The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients. 2012

Steven F L van Lelyveld, and Annemarie M J Wensing, and Andy I M Hoepelman
Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Huispostnummer F.02.126, Postbus 85500, 3508 GA Utrecht, The Netherlands. s.f.l.vanlelyveld@umcutrecht.nl

Although the use of combination antiretroviral therapy has resulted in spectacular improvements in morbidity and mortality of HIV-1 infected patients, a need for the development of antiretroviral compounds with new mechanisms of action remains. Maraviroc (Celsentri(®); ViiV Healthcare, Middlesex, UK) is the only drug of the class of chemokine (C-C motif) receptor 5 antagonists registered for treatment for HIV-1-infected antiretroviral therapy-experienced patients. Registration was based on the MOTIVATE-1 and -2 studies, which compared the efficacy and tolerability of maraviroc in combination with optimized background therapy with placebo. The aim of this paper is to review the MOTIVATE studies and to discuss issues related to maraviroc therapy in clinical practice such as assessment of HIV-1 coreceptor tropism.

UI MeSH Term Description Entries
D003510 Cyclohexanes Six-carbon alicyclic hydrocarbons.
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077592 Maraviroc A cyclohexane and triazole derivative that acts as an antagonist of the CCR5 RECEPTOR. It prevents infection by HIV-1 virus strains which use CCR5 as a co-receptor for membrane fusion and cellular entry. 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide,Selzentry,UK-427,857,UK-427857,UK 427,857,UK 427857,UK427,857,UK427857
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents
D056189 Viral Tropism The specificity of a virus for infecting a particular type of cell or tissue. Tropism, Viral,Virus Tropism,Tropism, Virus

Related Publications

Steven F L van Lelyveld, and Annemarie M J Wensing, and Andy I M Hoepelman
August 2013, CPT: pharmacometrics & systems pharmacology,
Steven F L van Lelyveld, and Annemarie M J Wensing, and Andy I M Hoepelman
May 2015, AIDS research and human retroviruses,
Steven F L van Lelyveld, and Annemarie M J Wensing, and Andy I M Hoepelman
December 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,
Steven F L van Lelyveld, and Annemarie M J Wensing, and Andy I M Hoepelman
January 2014, Journal of acquired immune deficiency syndromes (1999),
Steven F L van Lelyveld, and Annemarie M J Wensing, and Andy I M Hoepelman
August 2010, Journal of acquired immune deficiency syndromes (1999),
Steven F L van Lelyveld, and Annemarie M J Wensing, and Andy I M Hoepelman
June 2009, The Journal of antimicrobial chemotherapy,
Steven F L van Lelyveld, and Annemarie M J Wensing, and Andy I M Hoepelman
January 2010, HIV clinical trials,
Steven F L van Lelyveld, and Annemarie M J Wensing, and Andy I M Hoepelman
January 2007, AIDS reviews,
Steven F L van Lelyveld, and Annemarie M J Wensing, and Andy I M Hoepelman
September 2016, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!